Kymera Therapeutics Inc Stock News

Kymera Therapeutics' KT-474, partnered with Sanofi, is in Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis, with completion of studies expected mid-2026. KT-621, a STAT6 degrader for immuno-inflammatory disorders, shows promise with Phase 1 data expected in the first half of 2025. The company has $911 million in cash, sufficient to fund operations into mid-2027, covering key mi...

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - CFO Conference Call Participants Marc Frahm - TD Cowen Kalpit Patel - B. Riley Alexei Siniakov - Truist Securities Brad Canino - Stifel Nicolaus Gospel...

KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025

KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET.

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data from its innovative TPD platform will be presented across three poster presentations at the EORTC-NCI-AACR Symposium on Molecu...